Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Eli Lilly and Company
Study JGCB will consist of the following parts: Part 1 - Dose Escalation to maximum tolerated dose in each arm. Arm A - LY2584702 + Erlotinib in participants with advanced or metastatic cancer. Arm B - LY2584702 + Everolimus in participants with advanced or metastatic cancer. Part 2 - Dose Confirmation of maximum tolerated dose from each arm in Part 1. Arm A - LY2584702 + Erlotinib in participants with advanced or metastatic non-small cell lung cancer. Arm B - LY2584702 + Everolimus in participants with advanced renal cell carcinoma after treatment failure with sunitinib or sorafenib, or advanced neuroendocrine tumors.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted